1 Recommendations

Sr.­no.

Recommendations

SoR

QoE

1

The AGA recommends using linaclotide (over no drug treatment) in patients with IBS-C.
Comments: Patients who place a high value on avoiding diarrhea and avoiding higher out-of-pocket expenses associated with linaclotide may prefer alternate treatments.

Strong

High

Evidence for Recommendation 1

2

The AGA suggests using lubiprostone (over no drug treatment) in patients with IBS-C.
Comments: Patients who place a high value on avoiding higher out-of-pocket expenses associated with lubiprostone may prefer alternate treatments.

Cond

Mod

Evidence for Recommendation 2

3

The AGA suggests using laxatives (over no drug treatment) in patients with IBS-C.

Cond

Low

Evidence for Recommendation 3

4

The AGA suggests using rifaximin (over no drug treatment) in patients with IBS-D.

Cond

Mod

Evidence for Recommendation 4

5

The AGA suggests using alosetron (over no drug treatment) in patients with IBS-D to improve global symptoms.

Cond

Mod

Evidence for Recommendation 5

6

The AGA suggests using loperamide (over no drug treatment) in patients with IBS-D.

Cond

V Low

Evidence for Recommendation 6

7

The AGA suggests using tricyclic antidepressants (over no drug treatment) in patients with IBS.

Cond

Low

Evidence for Recommendation 7

8

The AGA suggests against using selective serotonin reuptake inhibitors for patients with IBS.

Cond

Low

Evidence for Recommendation 8

9

The AGA suggests using antispasmodics (over no drug treatment) in patients with IBS.

Cond

Low

Evidence for Recommendation 9

SoR: Strength of Recommendation
QoE: Quality of Evidence
Strong: Strong Recommendation
Cond: Conditional Recommendation
High: High-Quality Evidence
Mod: Moderate-Quality Evidence
Low: Low-Quality Evidence
V Low: Very Low-Quality Evidence
AGA: American Gastroenterological Association
IBS: Irritable bowel syndrome
IBS-C: Irritable bowel syndrome with constipation
IBS-D: Irritable bowel syndrome with diarrhea